According to the Zhitong Finance App, Tailing Pharmaceutical (01011) announced the audited annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 7.366 million yuan (RMB, same below) during the period, with no revenue in the same period of the previous year; shareholders should have accounted for a loss of 144 million yuan, an increase of 116.23% over the previous year; and a basic loss of 7.26 points per share.

The announcement stated that the increase in revenue was due to a change in the business model in 2023.